GSK

Post- Doctoral Investigator - Molecular Virology

Your Responsibilities
The goal of this post-doctoral project (funded for three years) is to develop a system for the rapid identification and testing of new vaccine candidates in response to an outbreak by an emerging pathogen.  This specific project is just one part of a wider effort within GSK Vaccines to further advance our nucleic acid-based vaccine platform called SAM, which is an engineered Self-Amplifying mRNA replicon designed and formulated for vaccine purposes.  SAM molecules have been shown to trigger a broad and robust immune responses to a number of encoded antigens in preclinical animal models.  The post-doctoral candidate will form part of a team of scientists from both GSK and external collaborators to advance this platform using state-of-the-art computational biology, genomics, and high-throughput workflows.

To be successful in the role, this person must:

-have the ability to understand, interpret, and communicate complex scientific data
-be comfortable conversing with opinion leaders regarding highly technical information
-be a self-starter able to handle multiple projects concurrently
-possess a good balance of creative, analytical, and communication skills
-be productive and successful in an intense work environment and he/she must be a Team Player

Why You?

Basic qualifications: 
-Ph.D. degree  and/or a M.D./Ph.D. in Virology, Molecular Virology, or Molecular Biology related disciplines
-Extensive expertise of cell biology and molecular biology techniques including cell-based assay development and screening, molecular cloning, and virology
-Hands-on experience in imaging technologies, including fluorescence and confocal microscopy
-Basic skills in statistical analysis
-Strong track-record of scientific publications in peer-reviewed journals, including at least one as a first author
-Fluency in English, spoken and written

Preferred qualifications: 
-Experience working with RNA viruses and manipulating viral systems
-Experience with high-throughput cell-based assay development and screening
-Experience with Next-generation sequencing technologies
-Excellent communication and presentation skills and the ability to collaborate in multiple project work streams

Why GSK?
In September 2015, GSK established a new global centre for vaccines research and development (R&D) in Rockville, Maryland.  The site is one of three global vaccines R&D centres for GSK, complementing the company’s existing global R&D centres in Rixensart, Belgium and in Siena, Italy.
The new US vaccines R&D centre will expand GSK’s efforts to discover and develop novel vaccines across a range of pressing public health threats, including those relevant to the US. It will consolidate vaccines R&D activities currently conducted at other GSK sites including in Philadelphia, PA and Cambridge, MA, into one centralised location. Key late stage development programmes, as well as vaccine discovery and new platform technology development will be led from Rockville.

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries. The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta (US) site dedicated to smallpox vaccine production since 1882.  Today, our vaccines continue to tackle some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Our Vaccines business has a portfolio of more than 40 vaccines for every stage of life, helping to protect people against 22 diseases. We have a pipeline of 14 candidate vaccines in development. One third of our vaccines in development target diseases particularly prevalent in the developing world, including all three WHO infectious disease priorities: HIV, malaria and TB. Our other vaccines in development include vaccines for the treatment of COPD and prevention of Respiratory Syncytial Virus (RSV). In October 2017, our shingles vaccine, Shingrix, received regulatory approval in Canada and the US.

GSK has a 150-year legacy of helping to transform the health, lives and futures of millions of people around the world.  We’re a science-led healthcare company with more than 100,000 people working in 115 countries. Each year we produce around 4 billion packs of medicine, nearly 900 million doses of vaccine and more than 18 billion packs of consumer healthcare products.  Our focus of helping people do more, feel better and live longer is at the center of all that we aim to do. 

At GSK, our mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Our three world-leading businesses research and deliver innovative medicines, vaccines and consumer healthcare products. We need a talented and motivated workforce to deliver against our strategy. To achieve this, we strive to attract the best people and to create an environment that empowers and inspires.

Contact information: 
You may apply for this position online by clicking here.